Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
NXP800 yields neither severe thrombocytopenia, nor any responses.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
